Admescope continues to be highly rated by the customers!
13 April 2021
The whole Admescope team wishes to thank all our customers, who spent few minutes of their valuable time to answer the customer satisfaction survey regarding the fiscal year 2020.
Admescope received an average score of 4.5/5 from the questionnaire, which measured our performance in quality, competence, flexibility, customer communication and turnaround time. The given feedback has been carefully evaluated with an aim to further improve our performance. A donation of 600 € based on the number of survey responses received was made to UNICEF as promised.
If you have any questions regarding the conducted survey, please contact our Head of Business Development Dr Miia Kovalainen.
An upcoming webinar - In vitro drug-drug interaction studies: What, when and why?
Interested to learn more about drug-drug interaction studies?
In the webinar on April 28th, Admescope’s Head of Enzyme Inhibitions, Transporters and PBPK Dr Aki Heikkinen will outline the mechanisms causing metabolism- and transporter-based interactions and illustrate the impact of interactions for both the ‘victim’ and ‘perpetrator’ of DDI. Furthermore, the routinely used in vitro methods for addressing DDI risks and translation of in vitro results into clinical predictions, and potential timing of such studies during drug discovery and development process are discussed.